What Genetic Technologies does

Genetic Technologies Limited (ASX: GTG) operates the geneType portfolio of personalized predictive genetic risk assessment tests, with the geneType trademark held by parent/affiliate Rhythm Biosciences. The company's core product is the patented Multi-Risk Test (MRT), a saliva/buccal-based integrated polygenic risk assessment that combines disease-associated single nucleotide polymorphisms with clinical and familial risk factors to generate absolute 5-year, 10-year and lifetime risk scores across multiple conditions — breast, colorectal, ovarian, prostate, pancreatic and melanoma cancers, plus atrial fibrillation, coronary artery disease and type 2 diabetes. Ten individual disease-specific tests are offered alongside the MRT, and all assays are processed in a CLIA-certified laboratory that has been delivering polygenic risk integrated assessments since 2011 and is accredited to ISO 15189 and NPAAC standards. Proprietary algorithms are specifically calibrated for the general population and have been validated against gold-standard clinical risk models in peer-reviewed publications presented at SABCS, ASCO and other venues, with granted patents across five patent families in the US, China and Hong Kong.

The business is a self-pay direct-to-consumer and provider-directed genetic testing model with per-test retail pricing at A$395 for a single geneType test and A$489 for a bundle of two or more, plus an option to use FSA/HSA funds. Tests are not generally covered by private health insurance or Medicare, and turnaround is 10–12 weeks from sample receipt. In the US, consumers order through the DNA Visit telehealth partner, complete a clinical questionnaire, receive a saliva collection kit, and obtain a results consultation before at-risk results are released. In Australia and for provider referrals, healthcare practitioners register accounts, distribute kits, and receive results with optional genetic counselor support. Revenue and ARR figures are not disclosed in the source material; the company has raised only US$2 million via an April 2024 registered direct offering of ADSs and warrants, supporting an early-stage commercial profile with ~51–100 employees and operations in the US and Australia.

Name

Genetic Technologies

Legal name

Genetic Technologies Limited

Website

https://genetype.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

51–100 employees

Short description

Genetic Technologies Limited (ASX: GTG) operates the geneType portfolio of saliva-based polygenic risk assessment tests, integrating genetic markers with clinical risk factors to predict risk of multiple cancers and cardiometabolic diseases for health-conscious adults and medical practitioners in the US and Australia on a self-pay basis.

Ownership category

akta.pro rank

Product category

Genetic Testing and Predictive Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic & Prenatal Testing Laboratories (HLAFAMAH)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Polygenic risk assessment
• Cancer risk testing
• Genetic diagnostics
• Preventive genomics
• Hereditary cancer screening

Headquarters

HQ city

Charlotte

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Genetic Testing Services: The company generates revenue through direct sales of genetic risk assessment tests to consumers and healthcare providers. Tests are ordered through a patient portal with telehealth partner oversight and shipped directly to consumers. The primary revenue model is direct self-pay with per-test pricing, though provider accounts and bulk ordering options are available.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Genetic Technologies sells the geneType portfolio of saliva-based polygenic risk assessment tests that integrate disease-associated genetic markers with clinical and familial risk factors to predict an individual's likelihood of developing multiple cancers and cardiometabolic conditions. Its flagship patented Multi-Risk Test screens up to eight diseases simultaneously, complemented by disease-specific tests for breast, colorectal, ovarian, prostate, melanoma, pancreatic, atrial fibrillation, coronary artery disease, and type 2 diabetes. Tests are run in a CLIA-certified laboratory and ordered either directly by consumers through a telehealth partner or by healthcare providers for their patients.

Product overview

GeneType is a world-leading portfolio of personalized predictive tests developed by Rhythm Biosciences (trademarked brand of Genetic Technologies). The platform uses a unique combination of genomic and clinical information to predict risk of chronic diseases including multiple cancers and cardiometabolic conditions. The core offering is the patented Multi Risk Test (MRT) that assesses multiple conditions simultaneously. The portfolio includes 10 disease-specific tests: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Melanoma, Pancreatic Cancer, Atrial Fibrillation, Coronary Artery Disease, and Type 2 Diabetes tests. All tests integrate polygenic risk scores (derived from SNPs) with traditional clinical risk factors to generate absolute risk scores that outperform gold-standard clinical models. Testing uses simple saliva/buccal sample collection with results delivered via healthcare providers or telehealth partners. The company also offers BREVAGenplus as a sub-brand for breast cancer risk assessment.

Differentiator

Problem solved

Functional benefit

Brands

• geneType™ Multi Risk Test (MRT): Comprehensive risk assessment test that assesses multiple conditions simultaneously including breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer and type 2 diabetes.
• geneType™ Breast Cancer Test
• geneType™ Colorectal Cancer Test
• geneType™ Ovarian Cancer Test
• geneType™ Prostate Cancer Test
• geneType™ Melanoma Test
• geneType™ Pancreatic Cancer Test
• geneType™ Atrial Fibrillation Test
• geneType™ Coronary Artery Disease Test
• geneType™ Type 2 Diabetes Test

Products and services

• geneType Multi Risk Test (MRT) Comprehensive polygenic-integrated risk assessment evaluating multiple conditions simultaneously (breast, colorectal, ovarian, prostate, melanoma, pancreatic cancers, atrial fibrillation, coronary artery disease, type 2 diabetes) from a single saliva sample. Provides lifetime and short-term absolute risk scores with actionable recommendations for screening and risk reduction. Launched 2021.
• geneType Breast Cancer Test Saliva-based polygenic risk test for breast cancer that integrates genetic markers, family history, age, BMI, breast density and menopausal status to deliver 5-year and lifetime risk predictions for sporadic breast cancer. Targeted at adult women, particularly those without HBOC mutations or significant family history.
• geneType Colorectal Cancer Test Polygenic risk test for colorectal cancer combining genetic markers with age, family history, BMI, screening status and triglycerides to deliver 10-year and lifetime risk predictions.
• geneType Ovarian Cancer Test Polygenic risk test for ovarian cancer targeting women aged 40 and older without known HBOC gene mutations, integrating genetic and clinical risk factors to provide actionable risk scores.
• geneType Prostate Cancer Test Polygenic risk test for prostate cancer combining polygenic risk with clinical and familial factors for men aged 30-85 years without known hereditary gene mutations.
• geneType Melanoma Test Polygenic risk test for melanoma providing lifetime and 10-year risk scores for adults aged 30-85 years based on genetic and clinical risk factors.
• geneType Pancreatic Cancer Test Polygenic risk test for pancreatic cancer delivering lifetime and 10-year risk scores for adults aged 30 and older without known hereditary gene mutations.
• geneType Atrial Fibrillation Test Polygenic risk test for atrial fibrillation providing 10-year risk scores for adults aged 40-85 years by integrating clinical and genetic risk factors.
• geneType Coronary Artery Disease Test Polygenic risk test for coronary artery disease providing 10-year risk scores by integrating Framingham model factors with polygenic risk and clinical/familial risk factors.
• geneType Type 2 Diabetes Test Polygenic risk test for type 2 diabetes providing 8-year risk scores for adults aged 40-85 years by integrating polygenic risk with clinical and familial factors.
• BREVAGenplus Proprietary genetic risk assessment test for breast cancer risk evaluation, with three core genetic markers protected under granted US patents. Operates as a sub-brand of the geneType portfolio.
• Hereditary Cancer Risk Test Hereditary cancer risk test for assessing inherited genetic predisposition to cancer, planned for commercialization in 2024 as part of the company's expansion beyond polygenic risk into hereditary testing.

Quantifiable outcome

• 40% of adults tested identified as at increased risk for at least 1 disease on the Multi-Risk Test, with nearly half having no family history of the disease
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Know Your LemonscoreGTM or Marketing PartnerRhythm and geneType are proud partners of Know Your Lemons, an international breast cancer education organization whose programs have reached over 2 billion people globally. The partnership supports breast cancer awareness through educational content and special promotional offers during Breast Cancer Awareness Month.
• DNA VisitcoreChannel Partner/ Reseller/ DistributorDNA Visit is the third-party telehealth partner enabling direct-to-consumer ordering of geneType tests in the US market. DNA Visit reviews clinical information, approves test eligibility, facilitates payment collection, ships test kits to patients, and conducts results consultation with patients before releasing at-risk results.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Exact Sciences (Cologuard): Leading cancer screening diagnostics company with Cologuard for colorectal cancer screening. Highly comparable to geneType's colorectal cancer risk assessment from a clinical use-case perspective, though Exact Sciences operates at much greater scale with established reimbursement.
• Invitae: Clinical genetics platform offering hereditary cancer, reproductive health, and proactive genetic testing. Competes with geneType in provider-directed hereditary and risk testing, though with broader menu and larger commercial infrastructure.
• Myriad Genetics: Established clinical genetics company with hereditary cancer testing (BRACAnalysis, myRisk) and broader oncology/risk assessment products. A more established clinical-grade competitor to geneType with deep provider relationships and payer reimbursement.
• Ambry Genetics: Clinical genetic testing laboratory offering hereditary cancer, cardiac, and reproductive genetic panels. A relevant comparable as a clinical lab with provider-focused distribution and broad hereditary cancer testing menu overlapping with geneType's planned hereditary cancer test.
• Natera: Clinical genetic testing company with a portfolio spanning reproductive health, oncology, and organ transplant. While Natera's focus is more on cell-free DNA testing, its clinical channel and payer footprint make it a relevant comparable in the broader genetic risk testing market.

Direct peers

• 23andMe: Direct-to-consumer genetic testing platform that has expanded into polygenic risk scores for conditions including breast cancer (BRCA report), prostate cancer, and cardiometabolic disease. Competes head-to-head with geneType in the consumer preventive genomics space with a much larger customer database and brand recognition.
• Color Genomics: Clinical genetic testing company offering hereditary cancer, cardiovascular, and pharmacogenomic tests to consumers and providers. Direct competitor in the integrated risk assessment category with a hybrid DTC-plus-employer GTM model.

Others

• Rhythm Biosciences: Identified parent/trademark holder of geneType. Listed ASX-listed biotech focused on colorectal cancer diagnostics. While it is the corporate parent rather than a competitor, it is materially relevant given the brand and IP relationship with Genetic Technologies.

Emerging players

• Genomic Prediction: Emerging genetic testing company applying PRS to disease risk prediction. Less established than geneType but operating in the same integrated polygenic risk category for reproductive and general disease risk applications.
• Helix: Population genomics and clinical genetic testing platform partnering with health systems and life sciences companies. Comparable to geneType in the integrated clinical-plus-genomic risk model space, with a more health-system-anchored distribution approach.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/genetype-limited
• Facebookfacebook.com/GeneTypeglobal

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genetic Technologies